Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018;20(11):E1107-1109. doi:
10.1001/amajethics.2018.1107.
Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.
Distinctions between treatment and enhancement, and between supposedly authentic and inauthentic tools, often inform judgments about what is morally acceptable in sport.
The differences between CBPR and traditional research have been enumerated, but how to overcome them is still up for discussion, collaboration with community members is advocated, and examples are given.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.